PPARγ and inflammatory bowel disease:: a new therapeutic target for ulcerative colitis and Crohn's disease

被引：56

作者：

Wada, K ^{[1
]}

Nakajima, A

Blumberg, RS

机构：

[1] Osaka Univ, Sch Dent, Dept Pharmacol, Osaka, Japan

[2] Yokohama City Univ Sch, Dept Internal Med 3, Yokohama, Kanagawa, Japan

[3] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

TRENDS IN MOLECULAR MEDICINE | 2001年 / 7卷 / 08期

关键词：

D O I：

10.1016/S1471-4914(01)02076-7

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that is known to play a central role in adipocyte differentiation and insulin sensitivity. Through work in several animal models of intestinal inflammation, it is now recognized that PPAR gamma also inhibits tissue injury associated with immune activation. These studies point to PPAR gamma as a novel anti-inflammatory mediator with broad therapeutic potential.

引用

收藏

页码：329 / 331

页数：3

相关论文

共 27 条

[1] Cell stress and MKK6b-mediated p38 MAP kinase activation inhibit tumor necrosis factor-induced IκB phosphorylation and NF-κB activation [J].

Alpert, D ;

Schwenger, P ;

Han, JH ;

Vilcek, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (32) :22176-22183

[2] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].

Barnes, PJ ;

Larin, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071

[3] Prospects for research in inflammatory bowel disease [J].

Blumberg, RS ;

Strober, W .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (05) :643-647

[4] Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development [J].

Braissant, O ;

Wahli, W .

ENDOCRINOLOGY, 1998, 139 (06) :2748-2754

[5] PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].

Chawla, A ;

Barak, Y ;

Nagy, L ;

Liao, D ;

Tontonoz, P ;

Evans, RM .

NATURE MEDICINE, 2001, 7 (01) :48-52

[6] Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (BPARγ) heterodimer:: A basis for new therapeutic strategies [J].

Desreumaux, P ;

Dubuquoy, L ;

Nutten, S ;

Peuchmaur, M ;

Englaro, W ;

Schoonjans, K ;

Derijard, B ;

Desvergne, B ;

Wahli, W ;

Chambon, P ;

Leibowitz, MD ;

Colombel, JF ;

Auwerx, J .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (07) :827-838

[7] LOW-DOSE CYCLOSPORINE FOR THE TREATMENT OF CROHNS-DISEASE [J].

FEAGAN, BG ;

MCDONALD, JWD ;

ROCHON, J ;

LAUPACIS, A ;

FEDORAK, RN ;

KINNEAR, D ;

SAIBIL, F ;

GROLL, A ;

ARCHAMBAULT, A ;

GILLIES, R ;

VALBERG, B ;

IRVINE, EJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (26) :1846-1851

[8]

Hafraoui S, 1999, GASTROENTEROLOGY, V116, pA689

[9] Phosphorylation meets ubiquitination:: The control of NF-κB activity [J].

Karin, M ;

Ben-Neriah, Y .

ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :621-+

[10] JNK or IKK, AP-1 or NF-ΚB, which are the targets for MEK kinase 1 action? [J].

Karin, M ;

Delhase, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9067-9069